https://www.statnews.com/2022/06/08/moderna-says-omicron-containing-booster-outperforms-current-vaccine/ Skip to Main Content * * * * Community Try STAT+ TODAY STAT * Contribute * Log In * Try STAT+ TODAY My Account * My Account * Billing * Log Out Try STAT+ My Account [ ] Search Cancel * TOPICS + Coronavirus + Health + Pharma + Biotech + Politics & Policy + Health Tech + In the Lab + Business + Artificial Intelligence + Vaccines + Health Disparities + Prescription Politics * OPINION + First Opinion + The Pharmalot View + Adam's Take + Matt's Take + Off the Charts * TEAM + Biotech & Pharma o Allison DeAngelis o Adam Feuerstein o Damian Garde o Matthew Herper o Meghana Keshavan o Kate Sheridan o Ed Silverman o Jonathan Wosen + Health Tech o Mario Aguilar o Katie Palmer o Mohana Ravindranath o Casey Ross + Business & Policy o Tara Bannow o Rachel Cohrs o Lev Facher o Nicholas Florko o Bob Herman + Health & Science o Eric Boodman o Helen Branswell o Angus Chen o Elizabeth Cooney o Isabella Cueto o Theresa Gaffney o Olivia Goldhill o Andrew Joseph o Megan Molteni o Usha Lee McFarling o Jennifer Adaeze Okwerekwu o Nicholas St. Fleur + Team o View All * EVENTS + Upcoming Industry Events + STAT Events + STAT Summits + 2022 STAT Health Tech Summit * PODCASTS + Color Code + First Opinion Podcast + The Readout LOUD * NEWSLETTERS * RESOURCES + STAT Trials Pulse + Reports + E-books * VIDEO * * STAT+ + STAT+ Exclusive analysis of biotech, pharma, and the life sciences Learn More o The Latest o My Account + Topics o Biotech o Pharma o Policy o Health Tech o Business + Columns o Adam's Take o Matt's Take o The Pharmalot View + Tools o CRISPR Trackr o Breakthrough Device Tracker o Drug Pricing Policy Cheat Sheet + Events o STAT+ Conversations o All STAT Events + Team o Biotech and Pharma o Health Tech o Politics and Policy o Health and Science Account * My Account * Billing * Subscribe * Log In * Help More * Community * Contribute * Group Subscriptions Follow Us * * * * * Trending: Coronavirus First Opinion Biotech Health Biotech Moderna says Omicron-containing booster outperforms current vaccine * Matthew Herper By Matthew Herper June 8, 2022 Reprints * * * * * * * * * moderna vaccine Karen Ducey/Getty Images * * * * * * * * * Moderna said Wednesday that using a new version of its Covid-19 vaccine as a booster led to a superior antibody response against the Omicron variant compared to its current shot. The company said it plans to submit its data to the Food and Drug Administration in the coming weeks and that it hopes that the new booster will be available in the late summer. Moderna's booster, called mRNA1273.214, is a bivalent vaccine, meaning it contains mRNA coding for the spike protein for both the original strain of the SARS-CoV-2 virus and the newer Omicron strain. The company had previously released data showing that a bivalent vaccine containing mRNA coding for the spike protein for the original virus and the protein from the Beta variant of SARS-CoV-2 provided better antibody protection than the original vaccine. advertisement Newsletters Sign up for Daily Recap A roundup of STAT's top stories of the day. [ ] Please enter a valid email address. [Sign up]Privacy Policy Leave this field empty if you're human: [ ] Moderna said giving vaccinated volunteers a boost with mRNA1273.214 increased geometric mean titers, a measure of antibody levels, eight-fold. The FDA has been holding public hearings on how to choose which strains of the SARS-CoV-2 virus should be included in booster shots in the fall and who should receive those shots. Another meeting on whether and how the SARS-CoV-2 strain composition of Covid-19 vaccines should be modified is being held on June 28. However, companies have warned that choices will need to be made soon in order for vaccines to be available in the fall. advertisement In a statement, Stephane Bancel, Moderna's CEO, said that the data mean this bivalent vaccine is "our lead candidate for a Fall 2022 booster." * * * * * * * * * About the Author Reprints Matthew Herper Matthew Herper Senior Writer, Medicine, Editorial Director of Events Matthew covers medical innovation -- both its promise and its perils. [email protected] @matthewherper Tags Coronavirus Create a display name to comment This name will appear with your comment [ ] There was an error saving your display name. Please check and try again. [Continue] Trending [] FDA advisers unanimously endorse Bluebird's gene therapy for rare... FDA advisers unanimously endorse Bluebird's gene therapy for rare disorder [] As reports of 'Paxlovid rebound' increase, Covid researchers scramble... As reports of 'Paxlovid rebound' increase, Covid researchers scramble for answers [] FDA advisers unanimously endorse Bluebird's gene therapy for rare... FDA advisers unanimously endorse Bluebird's gene therapy for rare disorder Recommended [] Listen: Applause-worthy cancer data, the long wait for Novavax,... Listen: Applause-worthy cancer data, the long wait for Novavax, & the next FDA controversy wastewater testing Wastewater monitoring: how to strengthen and sustain an important... Wastewater monitoring: how to strengthen and sustain an important public health tool Franklin faces Biospring Partners closes $245 million first fund as private... Biospring Partners closes $245 million first fund as private markets tense up Recommended Stories [330x400-00000000] Biotech FDA advisers unanimously endorse Bluebird's gene therapy for rare disorder By Damian Garde BUSINESS TEAM Biotech Promising results reported for new generation of CAR-T immunotherapy for myeloma By Angus Chen advertisement [330x400-00000000] Biotech The FDA's Pazdur on accelerated approval, single-arm studies, and his own future By Adam Feuerstein [330x400-00000000] Special Report 'How do you decide?': Cancer treatment's CAR-T crisis has patients dying on a waitlist By Angus Chen Shattered glass tube Hospitals Justice Department says sweeping lab test fraud in Texas involved dozens of doctors and front companies By Tara Bannow STAT Reporting from the frontiers of health and medicine Trending: * Coronavirus * First Opinion * Biotech * Health * Pharmalot * Pharma Back to top Company * About STAT * Awards * Contact Us * Careers & Internships * Contribute * Diversity & Inclusion * Licensing Stories * Our Team Account * About STAT+ * FAQs * Log In * Subscribe App & Other Products * STAT App * Newsletters * Podcasts * STAT Madness * STAT Reports * STAT Trials Pulse * STAT Wunderkinds Group Subscriptions * Contact Us * Request A Quote Advertising * Advertise With Us Events * Upcoming Industry Events * STAT Events * STAT Summits * Sponsor An Event * Privacy * Comment Policy * Terms * Do Not Sell my Data * (c)2022 STAT * * * * * * *